Vitalhub (VHI) AI Stock Analysis

• Market Cap: C$637.25M
• Dividend Yield: N/A
• Average Volume (3M): 148.97K
• Price to Earnings (P/E): 113.1
• Beta (1Y): 0.55
• Revenue Growth: 41.68%
• EPS Growth: -16.15%
• Country: CA
• Employees: 500
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 0.03
• Shares Outstanding: 61,332,874
• 10 Day Avg. Volume: 164,389
• 30 Day Avg. Volume: 148,972
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$15.07
• Price Target Upside: 45.04% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 62 Neutral
• Price Target: C$11.50 ▲(10.68% Upside)

Vitalhub's overall stock score is primarily driven by its strong financial performance, particularly its revenue growth and solid balance sheet. However, technical indicators suggest potential bearish momentum, and the high P/E ratio indicates overvaluation concerns. The absence of earnings call data and corporate events means these factors do not influence the score.

Vitalhub Business Overview & Revenue Model

Company Description

Vitalhub Corp., together with its subsidiaries, provides technology solutions for health and human service providers in Canada, the United States, the United Kingdom, Australia, Western Asia, and internationally. Its solutions include electronic healthcare record, case management, care coordination, patient flow and operational visibility, and mobile apps. The company was incorporated in 2010 and is based in Toronto, Canada.

How the Company Makes Money

Vitalhub generates revenue primarily through the sale of its software solutions and services to healthcare providers, including hospitals, clinics, and other healthcare institutions. The company employs a subscription-based model for many of its products, allowing clients to pay for ongoing access and support. Additionally, Vitalhub may earn revenue from consulting services, implementation support, and training programs that help healthcare organizations effectively integrate and utilize its software. Key partnerships with healthcare organizations and technology providers enhance its market reach and foster collaboration, contributing to its overall revenue growth.

Vitalhub Financial Statement Overview

Summary

Vitalhub exhibits strong revenue growth and maintains a healthy balance sheet with low leverage. While profitability margins have faced some pressure, the company remains financially stable. The decline in free cash flow growth is a concern that needs monitoring, but overall, the company is well-positioned in its industry with opportunities for improvement in profitability and cash flow management.

Income Statement

Vitalhub has demonstrated strong revenue growth with a 10.16% increase in TTM, indicating robust demand for its services. The gross profit margin remains high at 78.24%, showcasing efficient cost management. However, the net profit margin has slightly decreased to 3.79%, suggesting some pressure on profitability. The EBIT and EBITDA margins have also declined, indicating potential challenges in operational efficiency.

Balance Sheet

The company maintains a solid balance sheet with a low debt-to-equity ratio of 0.0044, reflecting minimal leverage and financial risk. The return on equity is modest at 3.12%, indicating room for improvement in generating returns for shareholders. The equity ratio is strong, suggesting a stable financial position with a significant proportion of assets funded by equity.

Cash Flow

Operating cash flow remains positive, but the free cash flow has declined by 9.40% in the TTM, indicating potential challenges in cash generation. The operating cash flow to net income ratio is healthy, suggesting good cash conversion from profits. However, the decline in free cash flow growth could signal potential liquidity concerns if not addressed.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	82.63M	68.59M	52.51M	39.97M	24.66M	13.79M
Gross Profit	66.85M	55.49M	42.81M	32.94M	19.43M	10.29M
EBITDA	13.66M	11.90M	10.38M	5.25M	1.12M	148.12K
Net Income	4.95M	3.00M	4.55M	1.21M	-1.95M	-2.17M
Balance Sheet
Total Assets	277.26M	207.19M	118.78M	106.19M	72.77M	64.08M
Cash, Cash Equivalents and Short-Term Investments	94.01M	56.57M	33.48M	17.45M	16.39M	23.39M
Total Debt	15.59M	608.76K	541.09K	882.20K	792.51K	987.89K
Total Liabilities	94.93M	62.33M	36.88M	30.79M	17.95M	13.77M
Stockholders Equity	182.33M	144.86M	81.91M	75.40M	54.82M	50.31M
Cash Flow
Free Cash Flow	13.44M	14.24M	20.18M	5.83M	-309.58K	294.35K
Operating Cash Flow	14.23M	15.13M	20.47M	6.12M	-49.97K	405.14K
Investing Cash Flow	-38.75M	-31.39M	-4.15M	-21.84M	-10.06M	-9.37M
Financing Cash Flow	48.57M	39.09M	-287.89K	16.40M	3.17M	30.37M

Vitalhub Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 10.39
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:VHI, the sentiment is Negative. The current price of 10.39 is below the 20-day moving average (MA) of 10.85, below the 50-day MA of 11.34, and below the 200-day MA of 11.11, indicating a neutral trend. The MACD of -0.09 indicates Negative momentum. The RSI at 47.43 is Neutral, neither overbought nor oversold. The STOCH value of 47.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:VHI.

Vitalhub Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VHI	62 Neutral	C$637.25M	113.06	3.23%	―	41.68%	-16.15%
KSI	61 Neutral	C$485.26M	942.59	0.99%	―	39.32%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ADK	51 Neutral	C$32.09M	-6.38	―	―	-47.10%	-19.32%
AIML	44 Neutral	C$12.70M	-1.47	-1143.80%	―	-64.23%	18.42%
UDOC	34 Underperform	$15.27M	-2.54	―	―	―	21.61%
AIDR	34 Underperform	C$67.52M	-5.13	-202.19%	―	―	40.17%

Vitalhub Corporate Events

VitalHub Schedules Q3 2025 Financial Results Release and Conference Call

VitalHub Corp. announced it will release its Q3 2025 financial results on November 6, 2025, followed by a conference call on November 7, 2025, led by CEO Dan Matlow and CFO Brian Goffenberg. This announcement is part of VitalHub’s ongoing efforts to maintain transparency with stakeholders and could impact its market positioning by providing insights into its financial health and strategic direction.

The most recent analyst rating on (TSE:VHI) stock is a Buy with a C$15.00 price target. To see the full list of analyst forecasts on Vitalhub stock, see the TSE:VHI Stock Forecast page.

VitalHub Expands UK Presence with Novari Health Deployment

VitalHub Corp. has announced the deployment of its Novari Health electronic referral and bed management workflow solution in the UK, marking its first implementation in the region. This deployment with the South West Provider Collaborative, a National Health Service-led partnership, aims to enhance mental health services for over 5.5 million people by improving patient flow and access to care. The technology provides real-time bed visibility and AI-enhanced analytics to optimize resource utilization and reduce wait times, thereby strengthening VitalHub’s position in the healthcare technology market.

The most recent analyst rating on (TSE:VHI) stock is a Hold with a C$11.50 price target. To see the full list of analyst forecasts on Vitalhub stock, see the TSE:VHI Stock Forecast page.

VitalHub Transitions to Ernst & Young as New Auditor

VitalHub Corp. has announced a change in its auditing firm, transitioning from MNP LLP to Ernst & Young LLP effective September 9, 2025. This change is part of routine corporate governance, with no reservations or reportable events noted in the previous auditor’s reports. The transition is expected to maintain transparency and compliance with continuous disclosure obligations, ensuring stakeholders are informed and the company’s financial integrity is upheld.

The most recent analyst rating on (TSE:VHI) stock is a Hold with a C$12.00 price target. To see the full list of analyst forecasts on Vitalhub stock, see the TSE:VHI Stock Forecast page.

VitalHub Secures $74.75 Million in Public Offering to Fuel Growth

VitalHub has successfully closed a $74.75 million bought deal public offering, fully exercising the over-allotment option. The funds raised will support the company’s growth initiative, particularly in acquiring third-party enterprises in the healthcare industry, which aligns with its strategy to enhance its market position and provide synergistic opportunities.

The most recent analyst rating on (TSE:VHI) stock is a Buy with a C$14.50 price target. To see the full list of analyst forecasts on Vitalhub stock, see the TSE:VHI Stock Forecast page.

VitalHub Announces $65 Million Public Offering

VitalHub Corp. has announced the filing of a prospectus supplement in connection with a ‘bought deal’ public offering to distribute over 5 million common shares, aiming to raise approximately $65 million. The offering, expected to close around August 20, 2025, is subject to regulatory approval and involves co-lead underwriters Cormark Securities Inc. and National Bank Financial Inc. The move is part of VitalHub’s strategy to strengthen its market position and expand its financial resources, potentially impacting its operations and stakeholders positively.

The most recent analyst rating on (TSE:VHI) stock is a Buy with a C$10.50 price target. To see the full list of analyst forecasts on Vitalhub stock, see the TSE:VHI Stock Forecast page.

VitalHub Corp. Announces $65 Million Public Offering to Fuel Growth

VitalHub Corp. has announced a $65 million bought deal public offering, with Cormark Securities Inc. and National Bank Financial Inc. acting as co-lead underwriters. The proceeds from this offering will be used for growth initiatives, including future acquisitions and general corporate purposes, with the closing expected around August 20, 2025, pending regulatory approval. This strategic move is expected to bolster VitalHub’s market position and support its aggressive growth strategy, potentially impacting stakeholders by enhancing the company’s operational capabilities and expanding its market reach.

The most recent analyst rating on (TSE:VHI) stock is a Buy with a C$10.50 price target. To see the full list of analyst forecasts on Vitalhub stock, see the TSE:VHI Stock Forecast page.

VitalHub Achieves Robust Financial Growth in Q2 2025

VitalHub reported significant financial growth in the second quarter of 2025, with annual recurring revenue up 55% year-over-year to $79.6 million and total revenue up 47% to $23.9 million. The company has successfully integrated its 2024 acquisitions, including Novari and Induction, enhancing its patient flow solutions and expanding its international presence. With over $40 million in cash and more than $90 million in ARR, VitalHub is well-positioned for continued expansion.

The most recent analyst rating on (TSE:VHI) stock is a Buy with a C$10.50 price target. To see the full list of analyst forecasts on Vitalhub stock, see the TSE:VHI Stock Forecast page.